论文部分内容阅读
短短几个月内,Agios制药早期药物AG-221针对各种血液癌症突出明显的迹象,在美国血液学会年度科学会议中,其公司在生物技术领域获得可喜的成果。Agios生物医药公司在研发领域取得了许多出色的成绩。就在公司宣布其开发的治疗白血病药物AG-221先行试验研究取得成功的几个月后,公司另外一项关于AG-221的探索试验又传来佳音。在此次小规模临床研究中研究人员招募了45名患有IDH2(异柠檬酸脱氢酶2)突变阳性的恶性肿瘤患者,以考察这些患者对AG-221的反应情况。这些患
In just a few months, Agios AG-221, an early drug for pharmaceuticals, has shown clear signs of various types of hematological cancers and its company has achieved gratifying results in biotechnology at the annual meeting of the American Society of Hematology. Agios Biomedical has achieved many outstanding results in research and development. Just months after the company announced the success of its pioneering pilot study on AG-221, a leukemia drug, the company also heard another good test on the AG-221. In this small-scale clinical study, 45 patients with malignant tumors positive for IDH2 (isocitrate dehydrogenase 2) mutation were recruited to investigate the response of these patients to AG-221. These patients